Atty Docket No.: R0147B-REG USSN: 10/663,314

REMARKS

Claims 1-25 are pending in the above-identified patent application. Claims 22 and 25 are amended herein. Claims 26-28 are canceled. No new matter is introduced.

1. Allowed Subject Matter

The Applicants note with appreciation that claims 1-21 and 24 are deemed allowable.

2. Rejoinder of Method Claims

The Examiner indicated that method claims (Groups III and V) which are commensurate in scope with allowable claim 1 could be rejoined, and that an Amendment resulting in method claims commensurate in scope with the allowed claims would be considered.

Applicants have accordingly amended method claim 22 (Group III) to depend from allowed claim 1 and include the limitations of claim 1. Previously withdrawn claim 23 depends from amended claim 22.

Method claim 25 (Group V) depends from allowable claim 1. Applicants have amended claim 25 to recite more specifically the treatment of 5-HT6-mediated memory disorders and Alzheimer's disease. Claims 26-28 have been canceled.

Applicants respectfully believe that amended claims 22 and 25 are commensurate in scope with allowable claim 1 and include only elected subject matter.

Atty Docket No.: R0147B-REG USSN: 10/663,314

CONCLUSION

In view of the foregoing, the Applicants respectfully believe that all claims pending in the above-identified case are now in condition for allowance. If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-354-7540. No fees are believed due, but if any fees are believed due, please charge the same to Deposit Account No. 18-1700.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-354-7540.

Respectfully submitted,

Roche Palo Alto
Patent Department, MS A2/250
Palo Alto, CA 94301

Phone: (650) 354-7540

June 14, 2006

Robert C. Hall Reg. No. 39,209

Attomey for Applicants